MTOR and angiomyolipoma: In contrast to the convincing data on the efficacy of mTOR inhibitors in patients with angiomyolipoma, the efficacy of these agents in the treatment of renal cystic disease associated with TSC has yet to be fully defined, but they have shown promising results in recent research20,58.